Skip to main content
NCBI home page
Journal of Clinical Microbiology logoLink to Journal of Clinical Microbiology
. 1995 Oct;33(10):2612–2615. doi: 10.1128/jcm.33.10.2612-2615.1995

Torulopsis glabrata: azole susceptibilities by microdilution colorimetric and macrodilution broth assays.

R N Tiballi 1, L T Zarins 1, X He 1, C A Kauffman 1
PMCID: PMC228540  PMID: 8567892

Abstract

Fluconazole and itraconazole MICs were determined by both the standard macrodilution method of the National Committee for Clinical Laboratory Standards and a colorimetric broth microdilution method for 140 isolates of Torulopsis (Candida) glabrata obtained over a 15-year period. Using the method of the National Committee for Clinical Laboratory Standards the MICs at which 90% of isolates are inhibited (MIC50) for all isolates were 32 and 1.6 micrograms/ml for fluconazole and itraconazole, respectively. For fluconazole, the MIC90 rose from 16 to > 64 micrograms/ml when the MIC90s for isolates collected from July 1980 to June 1991 were compared with those for isolates collected from July 1991 to March 1995. For itraconazole, the MIC90s for isolates from the same time periods were 0.8 and 3.2 micrograms/ml, respectively. Although for isolates from some non-human immunodeficiency virus-infected patients the MICs rose, most of the high MICs were found for isolates from human immunodeficiency virus-infected patients who had been extensively treated with azole drugs for thrush. The colorimetric method yielded endpoints that were more definitive; concordances within 2 dilutions for the two methods were 87% for fluconazole and 86% for itraconazole.

Full Text

The Full Text of this article is available as a PDF (182.9 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barchiesi F., Colombo A. L., McGough D. A., Rinaldi M. G. Comparative study of broth macrodilution and microdilution techniques for in vitro antifungal susceptibility testing of yeasts by using the National Committee for Clinical Laboratory Standards' proposed standard. J Clin Microbiol. 1994 Oct;32(10):2494–2500. doi: 10.1128/jcm.32.10.2494-2500.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Dermoumi H. In vitro susceptibility of fungal isolates of clinically important specimens to itraconazole, fluconazole and amphotericin B. Chemotherapy. 1994 Mar-Apr;40(2):92–98. doi: 10.1159/000239178. [DOI] [PubMed] [Google Scholar]
  3. Galgiani J. N. Susceptibility testing of fungi: current status of the standardization process. Antimicrob Agents Chemother. 1993 Dec;37(12):2517–2521. doi: 10.1128/aac.37.12.2517. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. He X., Tiballi R. N., Zarins L. T., Bradley S. F., Sangeorzan J. A., Kauffman C. A. Azole resistance in oropharyngeal Candida albicans strains isolated from patients infected with human immunodeficiency virus. Antimicrob Agents Chemother. 1994 Oct;38(10):2495–2497. doi: 10.1128/aac.38.10.2495. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Hitchcock C. A., Pye G. W., Troke P. F., Johnson E. M., Warnock D. W. Fluconazole resistance in Candida glabrata. Antimicrob Agents Chemother. 1993 Sep;37(9):1962–1965. doi: 10.1128/aac.37.9.1962. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Jones P. G., Kauffman C. A., McAuliffe L. S., Liepman M. K., Bergman A. G. Efficacy of ketoconazole v nystatin in prevention of fungal infections in neutropenic patients. Arch Intern Med. 1984 Mar;144(3):549–551. [PubMed] [Google Scholar]
  7. Kauffman C. A., Liepman M. K., Bergman A. G., Mioduszewski J. Trimethoprim/sulfamethoxazole prophylaxis in neutropenic patients. Reduction of infections and effect on bacterial and fungal flora. Am J Med. 1983 Apr;74(4):599–607. doi: 10.1016/0002-9343(83)91017-3. [DOI] [PubMed] [Google Scholar]
  8. Klein J. J., Watanakunakorn C. Hospital-acquired fungemia. Its natural course and clinical significance. Am J Med. 1979 Jul;67(1):51–58. doi: 10.1016/0002-9343(79)90073-1. [DOI] [PubMed] [Google Scholar]
  9. Komshian S. V., Uwaydah A. K., Sobel J. D., Crane L. R. Fungemia caused by Candida species and Torulopsis glabrata in the hospitalized patient: frequency, characteristics, and evaluation of factors influencing outcome. Rev Infect Dis. 1989 May-Jun;11(3):379–390. doi: 10.1093/clinids/11.3.379. [DOI] [PubMed] [Google Scholar]
  10. Nobre G., Mendes E., Charrua M. J., Cruz O. Ketoconazole resistance in Torulopsis glabrata. Mycopathologia. 1989 Jul;107(1):51–55. doi: 10.1007/BF00437589. [DOI] [PubMed] [Google Scholar]
  11. Pfaller M. A., Barry A. L. Evaluation of a novel colorimetric broth microdilution method for antifungal susceptibility testing of yeast isolates. J Clin Microbiol. 1994 Aug;32(8):1992–1996. doi: 10.1128/jcm.32.8.1992-1996.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Pfaller M. A., Grant C., Morthland V., Rhine-Chalberg J. Comparative evaluation of alternative methods for broth dilution susceptibility testing of fluconazole against Candida albicans. J Clin Microbiol. 1994 Feb;32(2):506–509. doi: 10.1128/jcm.32.2.506-509.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Pfaller M. A., Vu Q., Lancaster M., Espinel-Ingroff A., Fothergill A., Grant C., McGinnis M. R., Pasarell L., Rinaldi M. G., Steele-Moore L. Multisite reproducibility of colorimetric broth microdilution method for antifungal susceptibility testing of yeast isolates. J Clin Microbiol. 1994 Jul;32(7):1625–1628. doi: 10.1128/jcm.32.7.1625-1628.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Price M. F., LaRocco M. T., Gentry L. O. Fluconazole susceptibilities of Candida species and distribution of species recovered from blood cultures over a 5-year period. Antimicrob Agents Chemother. 1994 Jun;38(6):1422–1424. doi: 10.1128/aac.38.6.1422. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Rex J. H., Pfaller M. A., Barry A. L., Nelson P. W., Webb C. D. Antifungal susceptibility testing of isolates from a randomized, multicenter trial of fluconazole versus amphotericin B as treatment of nonneutropenic patients with candidemia. NIAID Mycoses Study Group and the Candidemia Study Group. Antimicrob Agents Chemother. 1995 Jan;39(1):40–44. doi: 10.1128/aac.39.1.40. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Rex J. H., Pfaller M. A., Rinaldi M. G., Polak A., Galgiani J. N. Antifungal susceptibility testing. Clin Microbiol Rev. 1993 Oct;6(4):367–381. doi: 10.1128/cmr.6.4.367. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Rex J. H., Rinaldi M. G., Pfaller M. A. Resistance of Candida species to fluconazole. Antimicrob Agents Chemother. 1995 Jan;39(1):1–8. doi: 10.1128/aac.39.1.1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Sangeorzan J. A., Bradley S. F., He X., Zarins L. T., Ridenour G. L., Tiballi R. N., Kauffman C. A. Epidemiology of oral candidiasis in HIV-infected patients: colonization, infection, treatment, and emergence of fluconazole resistance. Am J Med. 1994 Oct;97(4):339–346. doi: 10.1016/0002-9343(94)90300-x. [DOI] [PubMed] [Google Scholar]
  19. Sewell D. L., Pfaller M. A., Barry A. L. Comparison of broth macrodilution, broth microdilution, and E test antifungal susceptibility tests for fluconazole. J Clin Microbiol. 1994 Sep;32(9):2099–2102. doi: 10.1128/jcm.32.9.2099-2102.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Terpenning M. S., Bradley S. F., Wan J. Y., Chenoweth C. E., Jorgensen K. A., Kauffman C. A. Colonization and infection with antibiotic-resistant bacteria in a long-term care facility. J Am Geriatr Soc. 1994 Oct;42(10):1062–1069. doi: 10.1111/j.1532-5415.1994.tb06210.x. [DOI] [PubMed] [Google Scholar]
  21. Tiballi R. N., He X., Zarins L. T., Revankar S. G., Kauffman C. A. Use of a colorimetric system for yeast susceptibility testing. J Clin Microbiol. 1995 Apr;33(4):915–917. doi: 10.1128/jcm.33.4.915-917.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Warnock D. W., Burke J., Cope N. J., Johnson E. M., von Fraunhofer N. A., Williams E. W. Fluconazole resistance in Candida glabrata. Lancet. 1988 Dec 3;2(8623):1310–1310. doi: 10.1016/s0140-6736(88)92919-4. [DOI] [PubMed] [Google Scholar]
  23. White D. J., Johnson E. M., Warnock D. W. Management of persistent vulvo vaginal candidosis due to azole-resistant Candida glabrata. Genitourin Med. 1993 Apr;69(2):112–114. doi: 10.1136/sti.69.2.112. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Wingard J. R., Merz W. G., Rinaldi M. G., Johnson T. R., Karp J. E., Saral R. Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. N Engl J Med. 1991 Oct 31;325(18):1274–1277. doi: 10.1056/NEJM199110313251803. [DOI] [PubMed] [Google Scholar]
  25. Wingard J. R., Merz W. G., Rinaldi M. G., Miller C. B., Karp J. E., Saral R. Association of Torulopsis glabrata infections with fluconazole prophylaxis in neutropenic bone marrow transplant patients. Antimicrob Agents Chemother. 1993 Sep;37(9):1847–1849. doi: 10.1128/aac.37.9.1847. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. vanden Bossche H., Marichal P., Odds F. C., Le Jeune L., Coene M. C. Characterization of an azole-resistant Candida glabrata isolate. Antimicrob Agents Chemother. 1992 Dec;36(12):2602–2610. doi: 10.1128/aac.36.12.2602. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Clinical Microbiology are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES